Investigational drug · Phase 3
RLS-0071
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Hypoxic-Ischemic Encephalopathy, Steroid Refractory GVHD.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "RLS-0071"
First trial start
2023
Jul 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RLS-0071", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Hypoxic-Ischemic Encephalopathy
- Steroid Refractory GVHD
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "RLS-0071" as an intervention, largest first.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic HypothermiaPivotal-lookingRecruiting
ReAlta Life Sciences, Inc.Industry
NCT05778188 · 173 participants (planned) · Start Jul 27, 2023 · Primary completion Dec 2026
Drug: RLS-0071; Placebo · For: Hypoxic-Ischemic Encephalopathy
Sites: Little Rock, Arkansas; Orange, California; San Diego, California · 22 sites in all
ReAlta Life Sciences, Inc.Industry
NCT06343792 · 66 participants (planned) · Start Aug 31, 2024 · Primary completion Dec 2026
Drug: RLS-0071 · For: Steroid Refractory GVHD
Sites: Duarte, California; Los Angeles, California; Atlanta, Georgia · 11 sites in all
ReAlta Life Sciences, Inc.Industry
NCT05298787 · 56 participants · Start Jan 13, 2021 · Primary completion Aug 16, 2021
Drug: RLS-0071; Saline Placebo · For: Healthy Volunteer
Sites: Montreal, Canada
ReAlta Life Sciences, Inc.Industry
NCT05351671 · 30 participants · Start May 23, 2022 · Primary completion Sep 21, 2022
Drug: RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses); RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses) and 1 more · For: Healthy
Sites: Hanover, Germany
- Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseActive, not recruiting
ReAlta Life Sciences, Inc.Industry
NCT06175065 · 24 participants (planned) · Start Jan 25, 2024 · Primary completion Jun 2025
Drug: RLS-0071; Placebo · For: Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Sites: St. Petersburg, Florida; Glen Burnie, Maryland; Omaha, Nebraska · 4 sites in all
ReAlta Life Sciences, Inc.Industry
NCT04574869 · 0 participants · Start Jan 2021 · Primary completion Sep 2022
Drug: RLS-0071 10 mg/kg; RLS-0071 40 mg/kg and 3 more · For: Acute Lung Injury; ALI; COVID-19
Sites: Detroit, Michigan
Newest research
PubMed records naming it or its code names, newest first.
- The Anti-inflammatory Peptide RLS-0071 Reduces Immune Cell Recruitment and Oxidative Damage in a Neonatal Rat Model of Hypoxic-Ischemic Encephalopathy.
Jackson KG, Sampson AC, Cunnion KM, et al. · Am J Perinatol 2026
- RLS-0071, a novel anti-inflammatory agent, significantly reduced inflammatory biomarkers in a randomised human evaluation of mechanisms and safety study.
Cunnion K, Goss J, Hair P, et al. · ERJ Open Res 2024
- RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial RLS-0071-101.
Goss JM, Hair P, Kumar PS, et al. · Am J Case Rep 2023
- The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy.
Krishna NK, Cunnion KM, Parker GA · Front Immunol 2022
- Peptide inhibition of acute lung injury in a novel two-hit rat model.
Sampson AC, Lassiter BP, Gregory Rivera M, et al. · PLoS One 2021
- Classical complement pathway inhibition reduces brain damage in a hypoxic ischemic encephalopathy animal model.
Kumar P, Hair P, Cunnion K, et al. · PLoS One 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.